On Monday, Jan. 7, Michael Lavery at Piper Sandler initiated coverage of the beverage giant, with an overweight rating and a ...

Transocean (NYSE:RIG – Free Report) had its target price cut by TD Cowen from $6.50 to $5.50 in a research note issued to ...

Fintel reports that on January 8, 2025, TD Cowen downgraded their outlook for J. M. Smucker (NYSE:SJM) from Buy to Hold.

TD Cowen analyst Phil Nadeau maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today. The company’s shares opened ...

TD Cowen analyst Josh Jennings maintained a Buy rating on Alphatec Holdings (ATEC – Research Report) yesterday. The company’s shares closed ...

Fintel reports that on January 8, 2025, TD Cowen upgraded their outlook for Coca-Cola (NYSE:KO) from Hold to Buy. Analyst ...

The cost of prescription drugs is set to climb in 2025 and beyond, according to TD Cowen’s 30th Annual Drug Pricing survey.

El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when ...

Lisa Thomas, Managing Director and Deputy Head of Global Research at TD Cowen, discusses some of the key findings of a new TD Cowen report on the big investment themes of 2025, including shifting ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

“Two-thousand-twenty-four was a tough year for staples stocks, and 2025 is shaping up to be even tougher,” says TD Cowen ...

Rate hike expectations +30bps sequentially, though still below survey average. Biz growth & confidence stepped up ...